Artiva Shares Fall 30% as Company Discontinues Cell Therapy, Cuts Workforce 94%
Artiva Biotherapeutics discontinued its cell therapy after two patient deaths and cut its workforce by 94%.
Related stories
Siemens Shareholders Expected to Receive One Healthineers Share per Two Siemens Shares
Two people familiar with the matter told Reuters that Siemens shareholders are expected to receive one additional Siemens Healthineers share next year for every two Siemens shares
M impact | EQUITY | Nov 11, 2026, 09:44 AM UTC
CoreWeave Shares Rise After Company Sees Q4 Revenue Beating Forecasts
CoreWeave said it expects fourth-quarter revenue to beat analysts’ forecasts, alongside in-line third-quarter earnings. Its shares traded higher in premarket trading.
M impact | EQUITY | Nov 11, 2026, 09:43 AM UTC
ABN AMRO shares reverse course, fall 2.5%
L impact | EQUITY | Nov 11, 2026, 09:43 AM UTC
Siemens Shareholders Will Receive One Additional Healthineers Share For Every Two Siemens Shares They Hold — RTRS Cites Sources
L impact | EQUITY | Nov 11, 2026, 09:42 AM UTC
Hapag-Lloyd Raises Full-Year Earnings Outlook for Third Time
The German container shipping company cited strong freight rates and a stronger-than-expected fourth quarter. Its stock was up 2.4% at 0925 GMT.
M impact | EQUITY | Nov 11, 2026, 09:41 AM UTC
UPDATE 1-Hapag-Lloyd raises outlook for third time on strong freight rates
UPDATE 1-Hapag-Lloyd raises outlook for third time on strong freight rates Adds stock move, details
L impact | EQUITY | Nov 11, 2026, 09:41 AM UTC